Thrombotic complications after haematopoietic stem cell transplantation: early and late effects

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 1, 2009, Pages 137-145

  Tsakiris, Dimitrios A ^a   Tichelli, André ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

arterial disease; atherosclerosis; haematopoietic stem cell transplantation; microangiopathy; thromboembolism; thrombosis; veno occlusive disease

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHROMBIN; ANTIVITAMIN K; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOSPORIN; DEFIBROTIDE; HEPARIN; IMMUNOMODULATING AGENT; LOW MOLECULAR WEIGHT HEPARIN; NUCLEOTIDE DERIVATIVE; PROSTAGLANDIN E1; RAPAMYCIN; STEROID; TISSUE PLASMINOGEN ACTIVATOR; URSODEOXYCHOLIC ACID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ATHEROSCLEROSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; BONE MARROW TOXICITY; CATHETER THROMBOSIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DYSLIPIDEMIA; ECHOGRAPHY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMOSTASIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LIVER VENOOCCLUSIVE DISEASE; LUNG EMBOLISM; MICROANGIOPATHY; MYELOABLATIVE CONDITIONING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; TREATMENT OUTCOME; VEIN OCCLUSION; VEIN THROMBOSIS; WHOLE BODY RADIATION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; THROMBOSIS; TIME FACTORS;

EID: 61649105262     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.12.002     Document Type: Review

References (59)

1. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 354 (2006) 1813-1826
2. Pihusch R., Salat C., Schmidt E., et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 74 (2002) 1303-1309
3. Nadir Y., and Brenner B. Hemorrhagic and thrombotic complications in bone marrow transplant recipients. Thromb Res 120 (2007) S92-S98
4. Pihusch M. Bleeding complications after hematopoietic stem cell transplantation. Semin Hematol 41 (2004) 93-100
5. Gerber D.E., Segal J.B., Levy M.Y., et al. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 112 (2008) 504-510
6. Gonsalves A., Carrier M., Wells P.S., et al. Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 6 (2008) 1468-1473
7. Armenian S.H., and Bhatia S. Cardiovascular disease after hematopoietic cell transplantation - lessons learned. Haematologica 93 (2008) 1132-1136
8. Leblond V., Salehian B.D., Borel C., et al. Alterations in natural anticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients. Bone Marrow Transplant 11 (1993) 299-305
9. Collins P.W., Gutteridge C.N., O'Driscoll A., et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant 10 (1992) 499-506
10. Collins P., Jones B., Uthayakumar S., et al. Haemostatic changes in uncomplicated bone marrow transplants. Bone Marrow Transplant 7 Suppl. 2 (1991) 54
11. Brandao L.R., Kletzel M., Boulad F., et al. A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. Pediatr Blood Cancer 50 (2008) 1240-1246
12. Pihusch V., Rank A., Steber R., et al. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients. Transplantation 81 (2006) 1405-1409
13. Tsakiris D.A., Marbet G.A., Tichelli A., et al. Activation of endothelium-dependent hemostatic factors following bone marrow transplantation. Schweiz Med Wochenschr 125 (1995) 416-419
14. Tsakiris D.A., Luescher T.F., Loeffler B.M., et al. Endothelin in the early phase of bone marrow transplantation. Transplantation 57 (1994) 300-301
15. Fraser C.J., Bhatia S., Ness K., et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 108 (2006) 2867-2873
16. Ho V.T., Revta C., and Richardson P.G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 41 (2008) 229-237
17. Martinez M.T., Bucher C., Stussi G., et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 36 (2005) 993-1000
18. Biedermann B.C. Vascular endothelium and graft-versus-host disease. Best Pract Res Clin Haematol 21 (2008) 129-138
19. Tichelli A., Bucher C., Rovo A., et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 110 (2007) 3463-3471
20. Tichelli A., Passweg J., Wojcik D., et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 93 (2008) 1203-1210
21. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 110 (2007) 3784-3792
22. Tichelli A., and Gratwohl A. Vascular endothelium as 'novel' target of graft-versus-host disease. Best Pract Res Clin Haematol 21 (2008) 139-148
23. Pihusch M., Lohse P., Reitberger J., et al. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 78 (2004) 911-918
24. Lagro S.W., Verdonck L.F., Borel Rinkes I., et al. No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients. Bone Marrow Transplant 26 (2000) 1103-1106
25. Abdelkefi A., Ben R.N., Kriaa A., et al. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplant recipients. Bone Marrow Transplant 36 (2005) 885-889
26. Sartori M.T., Danesin C., Saggiorato G., et al. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost 9 (2003) 299-307
27. Tsantes A.E., Nikolopoulos G.K., Bagos P.G., et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost 97 (2007) 907-913
28. Pihusch M., Wegner H., Goehring P., et al. Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients. Transplantation 80 (2005) 1376-1382
29. Kaleelrahman M., Eaton J.D., Leeming D., et al. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). Hematology 8 (2003) 91-95
30. Watson H.G. Upper extremity deep vein thrombosis - not the same disease at a different site. J Thromb Haemost 6 (2008) 1267-1268
31. Flinterman L.E., Van Der Meer F.J., Rosendaal F.R., et al. Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost 6 (2008) 1262-1266
32. Linnemann B., Meister F., Schwonberg J., et al. Hereditary and acquired thrombophilia in patients with upper extremity deep-vein thrombosis. Results from the MAISTHRO registry. Thromb Haemost 100 (2008) 440-446
33. Lechner D., Wiener C., Weltermann A., et al. Comparison between idiopathic deep vein thrombosis of the upper and lower extremity regarding risk factors and recurrence. J Thromb Haemost 6 (2008) 1269-1274
34. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118 (1993) 255-267
35. Carreras E., Bertz H., Arcese W., et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92 (1998) 3599-3604
36. DeLeve L.D., Shulman H.M., and McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22 (2002) 27-42
37. Chopra R., Eaton J.D., Grassi A., et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 111 (2000) 1122-1129
38. Chalandon Y., Roosnek E., Mermillod B., et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 10 (2004) 347-354
39. Corbacioglu S., Greil J., Peters C., et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 33 (2004) 189-195
40. Dignan F., Gujral D., Ethell M., et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 40 (2007) 79-82
41. Richardson P.G., Murakami C., Jin Z., et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 100 (2002) 4337-4343
42. Haussmann U., Fischer J., Eber S., et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 91 (2006) 795-800
43. Bearman S.I., Shen D.D., Hinds M.S., et al. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 84 (1993) 724-730
44. Shulman H., Striker G., Deeg H.J., et al. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med 305 (1981) 1392-1395
45. Pettitt A.R., and Clark R.E. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 14 (1994) 495-504
46. Ruutu T., Barosi G., Benjamin R.J., et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 92 (2007) 95-100
47. Kojouri K., and George J.N. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 19 (2007) 148-154
48. Kentouche K., Zintl F., Angerhaus D., et al. von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation. Semin Thromb Hemost 32 (2006) 98-104
49. Shen N., Ffrench P., Guyotat D., et al. Expression of adhesion molecules in endothelial cells during allogeneic bone marrow transplantation. Eur J Haematol 52 (1994) 296-301
50. Chang D.M., Wang C.J., Kuo S.Y., et al. Cell surface markers and circulating cytokines in graft versus host disease. Immunol Invest 28 (1999) 77-86
51. Matsuda Y., Hara J., Osugi Y., et al. Serum levels of soluble adhesion molecules in stem cell transplantation-related complications. Bone Marrow Transplant 27 (2001) 977-982
52. Tsakiris D.A., Gratwohl A., Heim D., et al. VCAM-1/VLA-4 upregulation as a perpetuation loop in patients with chronic graft-versus-host disease. Bone Marrow Transplant 37 (2006) 93
53. Testa S., Manna A., Porcellini A., et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 18 (1996) 383-388
54. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 454S-545S
55. Baker K.S., Ness K.K., Steinberger J., et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplantation Survivor Study. Blood 109 (2007) 1765-1772
56. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 341 (1999) 14-21
57. Bearman S.I. Veno-occlusive disease of the liver. Curr Opin Oncol 12 (2000) 103-109
58. McDonald G.B., Sharma P., Matthews D.E., et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4 (1984) 116-122
59. Jones R.J., Lee K.S., Beschorner W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44 (1987) 778-783